Surfactant protein a in exhaled endogenous particles is decreased in chronic obstructive pulmonary disease (COPD) Patients: A Pilot Study

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Lärstad, Mona ^a   Almstrand, Ann Charlotte ^a   Larsson, Per ^a   Bake, Björn ^a   Larsson, Sven ^a   Ljungström, Evert ^b   Mirgorodskaya, Ekaterina ^a   Olin, Anna Carin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; SURFACTANT PROTEIN A; ALBUMINOID;

AGED; ARTICLE; CHEMICAL PARAMETERS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; EXHALATION; EXHALED PARTICLE; EXPLORATIVE STUDY; FEASIBILITY STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MALE; METHODOLOGY; PARTICLE NUMBER CONCENTRATION; PILOT STUDY; PROTEIN CONTENT; CASE CONTROL STUDY; DEMOGRAPHY; METABOLISM; PATHOPHYSIOLOGY;

AGED; ALBUMINS; CASE-CONTROL STUDIES; DEMOGRAPHY; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A;

EID: 84956536770     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144463     Document Type: Article

References (49)

1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012; 379 (9823):1341-51. doi: 10.1016/S0140-6736(11)60968-9 .
2. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. Available from: http://www.goldcopd.org/.
3. Sundblad BM, Jansson SA, Nystrom L, Arvidsson P, Lundback B, Larsson K. Chronic obstructive pulmonary disease (COPD) during the two last years of life-A retrospective study of decedents. PloS one. 2013; 8(12):e84110. doi: 10.1371/journal.pone.0084110
4. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. The New England journal of medicine. 1968; 278(25):1355-60. doi: 10.1056/NEJM196806202782501 .
5. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet. 2014. doi: 10.1016/S0140-6736(14)60446-3 .
6. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-Airway obstruction in chronic obstructive pulmonary disease. The New England journal of medicine. 2004; 350 (26):2645-53. doi: 10.1056/NEJMoa032158 .
7. Siddiqui S, Usmani OS. Small airways, big challenge: measuring the unseen? Nature medicine. 2012; 18(11):1619-21. doi: 10.1038/nm.2981 .
8. Galban CJ, Han MK, Boes JL, Chughtai KA, Meyer CR, Johnson TD, et al. Computed tomographybased biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nature medicine. 2012; 18(11):1711-5. doi: 10.1038/nm.2971
9. Burgel PR, Bourdin A, Chanez P, Chabot F, Chaouat A, Chinet T, et al. Update on the roles of distal airways in COPD. European respiratory review: An official journal of the European Respiratory Society. 2011; 20(119):7-22. doi: 10.1183/09059180.10010610 .
10. van den Berge M, ten Hacken NH, Cohen J, Douma WR, Postma DS. Small airway disease in asthma and COPD: clinical implications. Chest. 2011; 139(2):412-23. doi: 10.1378/chest.10-1210 .
11. Pastva AM, Wright JR, Williams KL. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proceedings of the American Thoracic Society. 2007; 4(3):252-7. doi: 10.1513/pats.200701-018AW
12. Madsen J, Tornoe I, Nielsen O, Koch C, Steinhilber W, Holmskov U. Expression and localization of lung surfactant protein A in human tissues. American journal of respiratory cell and molecular biology. 2003; 29(5):591-7. doi: 10.1165/rcmb.2002-0274OC .
13. Honda Y, Takahashi H, Kuroki Y, Akino T, Abe S. Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest. 1996; 109(4):1006-9. .
14. Betsuyaku T, Kuroki Y, Nagai K, Nasuhara Y, Nishimura M. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. The European respiratory journal. 2004; 24(6):964-70 10.1183/09031936.04.00064004
15. Ishikawa N, Hattori N, Tanaka S, Horimasu Y, Haruta Y, Yokoyama A, et al. Levels of surfactant proteins A and D and KL-6 are elevated in the induced sputum of chronic obstructive pulmonary disease patients: A sequential sputum analysis. Respiration; international review of thoracic diseases. 2011; 82 (1):10-8. doi: 10.1159/000324539 .
16. Mazur W, Toljamo T, Ohlmeier S, Vuopala K, Nieminen P, Kobayashi H, et al. Elevation of surfactant protein A in plasma and sputum in cigarette smokers. The European respiratory journal. 2011; 38 (2):277-84. doi: 10.1183/09031936.00110510 .
17. Ohlmeier S, Vuolanto M, Toljamo T, Vuopala K, Salmenkivi K, Myllarniemi M, et al. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. Journal of proteome research. 2008; 7(12):5125-32. doi: 10.1021/pr800423x .
18. Vlachaki EM, Koutsopoulos AV, Tzanakis N, Neofytou E, Siganaki M, Drositis I, et al. Altered surfactant protein-A expression in type II pneumocytes in COPD. Chest. 2010; 137(1):37-45. doi: 10.1378/chest. 09-1029 .
19. Khor YH, Teoh AK, Lam SM, Mo DC, Weston S, Reid DW, et al. Increased vascular permeability precedes cellular inflammation as asthma control deteriorates. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2009; 39(11):1659-67. doi: 10.1111/j.1365-2222.2009.03349.x .
20. Borrill ZL, Roy K, Singh D. Exhaled breath condensate biomarkers in COPD. The European respiratory journal. 2008; 32(2):472-86. doi: 10.1183/09031936.00116107 .
21. Casaburi R, Celli B, Crapo J, Criner G, Croxton T, Gaw A, et al. The COPD Biomarker Qualification Consortium (CBQC). Copd. 2013; 10(3):367-77. doi: 10.3109/15412555.2012.752807 .
22. Shaw JG, Vaughan A, Dent AG, O'Hare PE, Goh F, Bowman RV, et al. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). Journal of thoracic disease. 2014; 6(11):1532-47. doi: 10.3978/j.issn.2072-1439.2014.11.33
23. Nicola ML, Carvalho HBd, Yoshida CT, Anjos FMd, Nakao M, Santos UdP, et al. Young "healthy" smokers have functional and inflammatory changes in the nasal and the lower airways. Chest. 2014; 145 (5):998-1005. doi: 10.1378/chest.13-1355
24. Koczulla AR, Noeske S, Herr C, Koepke J, Jörres RA, Nell C, et al. Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients. Respiratory Medicine. 106 (1):120-6. doi: 10.1016/j.rmed.2011.06.015
25. Antczak A, Ciebiada M, Pietras T, Piotrowski WJ, Kurmanowska Z, Górski P. Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Arch Med Sci. 2012; 8(2):277-85. . doi: 10.5114/aoms.2012.28555
26. Montuschi P. Exhaled breath condensate analysis in patients with COPD. Clin Chim Acta. 2005; 356 (1-2):22-34. doi: 10.1016/j.cccn.2005.01.012 .
27. Fabian P, McDevitt JJ, DeHaan WH, Fung ROP, Cowling BJ, Chan KH, et al. Influenza Virus in Human Exhaled Breath: An Observational Study. PloS one. 2008; 3(7):e2691. doi: 10.1371/journal.pone. 0002691
28. Fennelly KP, Martyny JW, Fulton KE, Orme IM, Cave DM, Heifets LB. Cough-generated Aerosols of Mycobacterium tuberculosis. American journal of respiratory and critical care medicine. 2004; 169 (5):604-9. doi: 10.1164/rccm.200308-1101OC
29. Huynh KN, Oliver BG, Stelzer S, Rawlinson WD, Tovey ER. A New Method for Sampling and Detection of Exhaled Respiratory Virus Aerosols. Clinical Infectious Diseases. 2008; 46(1):93-5. doi: 10.1086/523000
30. Lindsley WG, Blachere FM, Thewlis RE, Vishnu A, Davis KA, Cao G, et al. Measurements of airborne influenza virus in aerosol particles from human coughs. PloS one. 2010; 5(11):e15100. doi: 10.1371/journal.pone.0015100
31. Effros RM, Su J, Casaburi R, Shaker R, Biller J, Dunning M. Utility of exhaled breath condensates in chronic obstructive pulmonary disease: A critical review. Current opinion in pulmonary medicine. 2005; 11(2):135-9. .
32. Fairchild CI, Stampfer JF. Particle concentration in exhaled breath. Am Ind Hyg Assoc J. 1987; 48 (11):948-9. doi: 10.1080/15298668791385868 .
33. Papineni RS, Rosenthal FS. The size distribution of droplets in the exhaled breath of healthy human subjects. J Aerosol Med. 1997; 10(2):105-16. .
34. Schwarz K, Biller H, Windt H, Koch W, Hohlfeld JM. Characterization of exhaled particles from the human lungs in airway obstruction. Journal of aerosol medicine and pulmonary drug delivery. 2015; 28 (1):52-8. doi: 10.1089/jamp.2013.1104 .
35. Almstrand AC, Ljungstrom E, Lausmaa J, Bake B, Sjovall P, Olin AC. Airway monitoring by collection and mass spectrometric analysis of exhaled particles. Analytical chemistry. 2009; 81(2):662-8. doi: 10. 1021/ac802055k .
36. Almstrand AC, Bake B, Ljungstrom E, Larsson P, Bredberg A, Mirgorodskaya E, et al. Effect of airway opening on production of exhaled particles. Journal of applied physiology. 2010; 108(3):584-8. doi: 10. 1152/japplphysiol.00873.2009 .
37. Larsson P, Mirgorodskaya E, Samuelsson L, Bake B, Almstrand AC, Bredberg A, et al. Surfactant protein A and albumin in particles in exhaled air. Respir Med. 2012; 106(2):197-204. doi: 10.1016/j.rmed. 2011.10.008 .
38. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. General considerations for lung function testing. The European respiratory journal. 2005; 26(1):153-61. doi: 10.1183/09031936. 05.00034505 .
39. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations. The European respiratory journal. 2012; 40(6):1324-43. doi: 10.1183/09031936.00080312
40. Holmgren H, Bake B, Olin AC, Ljungstrom E. Relation between humidity and size of exhaled particles. Journal of aerosol medicine and pulmonary drug delivery. 2011; 24(5):253-60. doi: 10.1089/jamp. 2011.0880 .
41. Koulouris NG, Valta P, Lavoie A, Corbeil C, Chasse M, Braidy J, et al. A simple method to detect expiratory flow limitation during spontaneous breathing. The European respiratory journal. 1995; 8(2):306-13
42. Kingma PS, Whitsett JA. In defense of the lung: surfactant protein A and surfactant protein D. Current opinion in pharmacology. 2006; 6(3):277-83. doi: 10.1016/j.coph.2006.02.003 .
43. Henriksen JH, Kok-Jensen A. Normal overall leakiness of microvasculature for albumin in patients with chronic obstructive lung disease (COLD). Scandinavian journal of clinical and laboratory investigation. 1984; 44(2):119-23. .
44. Minakata Y, Nakanishi M, Hirano T, Matsunaga K, Yamagata T, Ichinose M. Microvascular hyperpermeability in COPD airways. Thorax. 2005; 60(10):882. doi: 10.1136/thx.2005.045765
45. Bernard A, Marchandise FX, Depelchin S, Lauwerys R, Sibille Y. Clara cell protein in serum and bronchoalveolar lavage. The European respiratory journal. 1992; 5(10):1231-8. .
46. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. American journal of respiratory and critical care medicine. 1999; 160(3):893-8. doi: 10.1164/ajrccm.160.3.9901091 .
47. Ropcke S, Holz O, Lauer G, Muller M, Rittinghausen S, Ernst P, et al. Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. PloS one. 2012; 7(10):e46207. doi: 10.1371/journal.pone.0046207
48. Yigla M, Berkovich Y, Nagler RM. Oxidative stress indices in COPD-Broncho-Alveolar lavage and salivary analysis. Archives of oral biology. 2007; 52(1):36-43. doi: 10.1016/j.archoralbio.2006.08.002 .
49. Persson C, Uller L. Roles of plasma exudation in asthma and COPD. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2009; 39(11):1626-9. doi: 10.1111/j. 1365-2222.2009.03373.x